Welcome to Markets Desk, your midday read on what's moving markets and why.
Citigroup is sounding a clear warning on the durability of this year's equity rally, telling clients that artificial intelligence has been the single biggest driver of earnings revisions higher, and that any meaningful slowdown in AI model development could pull that support away quickly. The bank isn't predicting a collapse, but the message is direct — concentration risk in AI-linked names is real, and the margin for disappointment is thin.
Shifting to biotech, BioNTech and OncoC4 released updated trial data showing their drug gotistobart nearly doubled median overall survival versus standard chemotherapy in previously treated squamous non-small cell lung cancer patients. That's a meaningful clinical signal in a disease area with historically limited options, and it adds weight to BioNTech's pipeline narrative beyond its COVID franchise.
Meanwhile, in the nuclear energy space, Oklo shares have been under pressure this month after the company announced a one billion dollar at-the-market equity offering on September eleventh, triggering a sharp selloff. The question investors are wrestling with is whether the dilution reflects opportunistic capital raising into strength, or signals a longer runway to profitability than the market had priced in.
That's the tape. Markets Desk, signing off the floor.
